Clinical trials: Hair Condition
Tinea Capitis
Safety and Efficacy of NAFT900 in Children With Tinea Capitis
A Double-Blind, Randomized, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of NAFT-900 in Children Aged 6 to < 13 Years with Tinea Capitis
- Trial name
- NCT02658292
- Testing
- Naftifine hydrochloride foam, 3%, Vehicle
- Sponsor
- Merz North America, Inc.
Trichotillomania, Hair Pulling Disorder
Milk Thistle in Trichotillomania in Children and Adults
The goal of the proposed study is to evaluate the efficacy and safety of silymarin (milk thistle) in children and adults with trichotillomania.
- Trial name
- NCT02473913
- Testing
- Milk Thistle
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Chicago
Alopecia Scar
Treatment of Alopecic Scars by Follicular Unit Extraction Hair Transplantation
This study aim: is to completely hide the alopecic scars in a way that it will not be visible.
- Trial name
- NCT06145672
- Testing
- follicular unit extraction and implantaion
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Assiut University
Graft vs Host Disease, Chronic Graft vs Host Disease
Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease
This research study will help us learn more about how chronic graft-versus-host disease affects the skin, hair and nails. We are interested in knowing if hair and nail problems predict worse disease.
- Conditions
- Graft vs Host Disease, Chronic Graft vs Host Disease, cGVHD
- Trial name
- NCT01221766
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
Alopecia Areata
Litfulo Capsules Special Investigation
The objective of this Study is to confirm the safety during the long-term use of this drug and the effectiveness during the use of this drug under the actual use in the patients treated with this drug.
- Trial name
- NCT06279221
- Testing
- LITFULO
- Where
- Japan
- Volunteers
- 664 people
- Sponsor
- Pfizer
Alopecia Areata
CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry
Prospective observational registry focusing on an adolescent cohort diagnosed with severe alopecia areata,receiving routine care from dermatology providers.
- Trial name
- NCT06562270
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- CorEvitas
Alopecia Areata, Alopecia Totalis
Alopecia Areata Registry
Alopecia areata is the loss of hair in patches that can proceed to loss of all hair (alopecia totalis or universalis). The purpose of the registry is to collect patient information and blood samples from people with alopecia…
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis, Autoimmune Hair Loss
- Trial name
- NAAR (NCT00069589)
- Where
- 5 sites in United States
- Volunteers
- 3,100 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Alopecia Areata
Evaluation of the Effect of Topical Calcipotriol Versus Platelet-Rich Plasma
Alopecia areata (AA) is a common, immune-mediated non scarring alopecia and can be associated with severe psychological consequences . Alopecia Areata affects 2% of the global population.
- Trial name
- NCT05954104
- Testing
- Calcipotriol
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Egymedicalpedia
Androgenetic Alopecia (AGA)
Clinical Study of PRP in the Treatment of Androgenetic Alopecia
A study on the therapeutic effect of platelet-rich plasma in the treatment of androgenetic alopecia
- Trial name
- NCT07551271
- Testing
- PRP
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Alopecia Areata
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata
Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and face, but hair loss can happen on any part of the body.
- Trial name
- Jump Up AA JP (NCT07023302)
- Testing
- Upadacitinib
- Where
- 15 sites in Japan
- Volunteers
- 125 people
- Sponsor
- AbbVie
Alopecia Areata
Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US
Alopecia areata (AA) is a chronic, relapsing T-cell mediated autoimmune disease characterized by nonscarring, typically patchy hair loss that affects people of all ages, races, and genders.
- Trial name
- NCT07226531
- Testing
- Ritlecitinib
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Pfizer
Alopecia Areata
Efficacy of Fractional CO2 Laser as a Mono- or Adjuvant Therapy for Alopecia Areata
Alopecia areata is a non-scarring hair loss disorder that affects both sexes equally. Incidence of the disease varies for different populations and in different studies, with global incidence ranging from 0.57% to 3.8%.
- Trial name
- NCT04003376
- Testing
- fractional carbon dioxide laser alone, Triamcinolone Acetonide 10mg/mL, platelet rich plasma
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Assiut University
Alopecia, Sensitive Skin
A Scalp Lotion Toimprove Sensitive Scalp Syndrome
Overall, 100 Caucasian subjects participated in this 6-weeks lasting study, AC5+ was applied daily. All subjects had clinically confirmed mild to moderate alopecia and self-declared sensitive scalp.
- Trial name
- NCT05630027
- Testing
- Piroctone Olamine (PO), 2,4 Diaminopyrimidine oxide (2.4 DA) and Vichy mineralizing water
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Cosmetique Active International
Areata Alopecia, Alopecia
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age.
- Conditions
- Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases
- Trial name
- BRAVE-AA-PEDS (NCT05723198)
- Testing
- Baricitinib
- Where
- 127 sites in United States, Argentina and 10 more
- Volunteers
- 595 people
- Sponsor
- Eli Lilly and Company
Alopecia Areata
Intralesional Vitamin D in Alopecia Areata
To evaluate the efficacy and safety of intralesional injection of vitamin D3 versus intralesional injection of corticosteroids in treatment of alopecia areata.
- Trial name
- NCT04660786
- Testing
- triamcinolone acetonide, vitamin D
- Where
- Egypt
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Alexandria University
Alopecia Areata
Topical Calcipotriol Versus Narrowband Ultraviolet B in Treatment of Alopecia Areata
Alopecia Areata is a common condition. This study investigated the efficacy of calcipotriol versus Narrow Band Ultraviolet B in treatment of Alopecia areata and their effects on serum vitamin D3 levels.
- Trial name
- NCT03847441
- Testing
- Calcipotriol, Narrow Band UVB, vitamin D3 level
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Aswan University Hospital
Alopecia Areata
Topical Crisaborole in Patients with Alopecia Areata
The aim of this study is to determine whether topical crisaborole improves hair growth in alopecia areata.
- Trial name
- NCT04299503
- Testing
- Crisaborole Topical Ointment
- Where
- United States
- Sponsor
- Tufts Medical Center
Spinal Muscular Atrophy, Fragile X Syndrome
Early Check: Expanded Screening in Newborns
Early Check provides voluntary screening of newborns for a selected panel of conditions. The study has three main objectives: 1) develop and implement an approach to identify affected infants, 2) address the impact on infants and…
- Conditions
- Spinal Muscular Atrophy, Fragile X Syndrome, Fragile X - Premutation, Duchenne Muscular Dystrophy
- Trial name
- NCT03655223
- Testing
- Confirmatory Testing
- Where
- United States
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- RTI International
Alopecia Areata
Methotrexate Versus Triamcinilone Acetonide in Treatment of Recalcitrant Alopecia Areata
Alopecia areata is the second most common cause of hair loss following androgenic alopecia. It is affecting 2% of global population with an increasing prevalence.
- Trial name
- NCT06088147
- Testing
- Methotrexate, Triamcinolone Acetonide
- Where
- Egypt
- Volunteers
- 34 people
- Sponsor
- Al-Azhar University
Pilonidal Disease
Pilot Study of Laser Hair Depilation for Pilonidal Disease
Pilot study to assess tolerability and safety of laser hair depilation in adolescents and young adults with pilonidal disease.
- Trial name
- NCT02778152
- Testing
- Laser depilation
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Peter Minneci